Philip McKinney, DPM
Foot & Ankle Surgery · Eugene, ORNPI 1619047206
Payments from drug & device makers
What this record shows
Treace Medical Concepts, Inc. accounts for 76.8% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $1,699 and has fallen 96.8% since, to $54 in 2025.
Across 30 payments — averaging $125.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Treace Medical Concepts, Inc.$3K
- Amgen$179
- Relievant Medsystems, Inc.$149
- GRT US Holding, Inc.$130
- Medtronic$97
- AbbVie$75
- plus $244 from 9 others
What the payments were for
- Travel & lodging$1,62543%
- Food & beverage$2,15057%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Treace Medical Concepts, Inc. | 12 | $2,901 |
| Amgen(2 entities) | 2 | $179 |
| Relievant Medsystems, Inc. | 1 | $149 |
| GRT US Holding, Inc. | 1 | $130 |
| Medtronic | 1 | $97 |
| AbbVie | 1 | $75 |
| Paragon 28, Inc. | 1 | $69 |
| Heron Therapeutics, Inc. | 2 | $38 |
| Smith+Nephew | 2 | $36 |
| Stryker | 2 | $29 |
| Nevro Corp. | 1 | $24 |
| Convatec Inc. | 1 | $15 |
| Organogenesis Inc. | 1 | $14 |
| Bioventus LLC | 1 | $14 |
| Orthofix Medical, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lapiplasty System$2,770
- Intracept$149
- Qutenza$130
How this compares
$3,775 in reported general payments places this provider in the 60th percentile of 113 foot & ankle surgery providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Flucytosine | 12 | $21,556 |
| Gentamicin Sulfate | 11 | $1,457 |
| Ketoconazole | 16 | $748 |
| Doxycycline Hyclate | 32 | $340 |
| Clindamycin Hcl | 15 | $318 |
| Cephalexin | 24 | $316 |
| Tramadol Hcl | 11 | $179 |
| Terbinafine Hcl | 15 | $151 |
| Mupirocin | 17 | $148 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Eugene
- Lyle JacksonEugene$8K
- Christopher CychoszEugene$8K
- Thomas YatesEugene$4K
- Drew PearsonEugene$3K
- Jacob GreenEugene$3K
- Natalie MesnierPortland$339K
- Stephen WallaceLake Oswego$205K
- Scott BoyntonPortland$120K
- Andrew ShinabargerPortland$85K
- Cassandra TomczakTualatin$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.